Adam Dahlberg
Chairman since 1999
Swedish technology investor within new materials, life science, medtech and software
Holding in the company: 3 532 136 shares private and through companies
Independent in relation to major shareholders: No
Independent in relation to the company and management: Yes
Education: Master Economics from Stockholm School of Economics
Other assignments: Chariman Corline Biomedical AB (publ.) and Senzime AB (publ.)